$1.26
+0.00 (+0.00%)
Open$1.28
Previous Close$1.26
Day High$1.31
Day Low$1.24
52W High$3.82
52W Low$0.77
Volume—
Avg Volume491.5K
Market Cap76.47M
P/E Ratio—
EPS$-0.54
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,023.8% upside
Current
$1.26
$1.26
Target
$14.16
$14.16
$9.87
$14.16 avg
$18.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 59.3K | 3.88M | 19.24M |
| Net Income | -18,822,254 | -160,579,998 | -3,136,016 |
| Profit Margin | -33,044.0% | -4,364.5% | -16.3% |
| EBITDA | -19,664,068 | -164,610,909 | -4,591,050 |
| Free Cash Flow | — | — | -2,958,449 |
| Rev Growth | — | -40.3% | -5.9% |
| Debt/Equity | 0.91 | 0.91 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |